Working at the interface between nanotechnology and the life sciences, Keystone Nano Inc is commercializing Ceramide NanoLiposome and additional products using NanoJackets, non-toxic calcium phosphate nanoparticles that may be actively targeted to specific cell types, for a variety of medical applications: nanoscale solutions for the treatment of cancer and improvements in industrial chemistries. The firm was granted an exclusive license for Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles calledNanoJackets(TM). Based on work undertaken while at Penn by the firm's Chief Medical Office, NanoJackets can encapsulate drugs and/or fluorescent molecules. Keystone Nano offers NanoJacket and NanoLiposome technology platforms that are used as drug delivery vehicles for the treatment of solid-tumor and non-solid-tumor cancers. The company also offers NanoJackets that protect active ingredients during industrial processing and selectively deliver them to achieve the desired industrial effect, as well as help academic researchers with a range of chemical, materials, and biological investigations; and NanoLiposomes that carry ceramide and other compounds of interest. I
